Abstract
Preimplantation genetic testing for aneuploidy (PGT-A) is one of the most controversial topics in reproductive medicine, with disagreements over the apparently contradictory results of randomised controlled trials, non-selection trials and outcome data analyses. Data from live birth outcomes largely suggest that fully euploid biopsies are associated with positive live birth rates, while fully aneuploid biopsies are not. However, the possible confounding effects of chromosomal mosaicism (when either the whole embryo, the biopsy result (or both) contain an admixture of euploid and aneuploid cells) is frequently cited as a reason why PGT-A should not be performed. Previous computer models have indicated that a mosaic result is a poor indicator of the level of mosaicism of the rest of the embryo, and it is thus unwise to use mosaic PGT-A results when selecting embryos for transfer. Here we developed a computational model, tessera, to create virtual embryos for biopsy, allowing us to vary the number of cells in the simulated embryo and biopsy, the proportion of aneuploid cells and the degree of juxtaposition of those cells. Analysis of approximately 1 million virtual embryos showed that “100% euploid” and “100% aneuploid” biopsy results are relatively accurate predictors of the remainder of the embryo, while mosaic biopsy results are poor predictors of the proportion of euploid and aneuploid cells in the rest of the embryo. Within mosaic embryos, ‘clumping’ of aneuploid cells further reduces the accuracy of biopsies in assaying the true aneuploidy level of any given embryo. Nonetheless - and somewhat counterintuitively - biopsy results can still be used with some confidence to rank embryos within a cohort. Our simulations help resolve the apparent paradox surrounding PGT-A: the biopsy result is poorly predictive of the absolute level of mosaicism of a single embryo, but may be applicable nonetheless in making clinical decisions on which embryos to transfer.
Competing Interest Statement
DKG consults for, and has ongoing projects with, Care Fertility, Igenomix, Conceivable, Cooper and London Women's Clinic. BMS, MV and PJIE have no competing interests to declare.
Funding Statement
BMS is supported by HEFCE/UKRI funding (University of Essex). PJIE is supported by HEFCE/UKRI funding (University of Kent).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses of clinical data were approved by the IRB of the Zouves Foundation (OHRP IRB00011505, Protocol #0002).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Scripts used perform the modelling in this paper are available at https://github.com/bmskinner/embryo_biopsy. IRMET data is available upon request.
